![]() |
|
|
Vol. 29, Issue 10, 1332-1336, October 2001
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development Groton, Connecticut
| |
Abstract |
|---|
|
|
|---|
The influence of microsomal concentration on unbound fraction (fumic), half-life (t1/2), apparent intrinsic clearance (CLint,app) and apparent Michaelis-Menten constant (Km,app) was examined for two compounds, one representative of high nonspecific binding to microsomes (compound A) and one representative of low (compound B). Kinetic parameters were estimated for the two probe compounds at two human microsomal protein concentrations (0.46 and 2.3 mg/ml) and cytochrome P450 concentrations (0.20 and 1.0 µM), representing a 5-fold difference in microsomal concentration. For compound A, fumic and CLint,app were inversely proportional to microsomal concentration. Conversely, the Km,app of compound A was proportional to microsomal concentration and the half-life was unchanged. For compound B, half-life was inversely proportional to microsomal concentration. In this case, fumic, CLint,app, and Km,app were not proportionally influenced. The experimental observations were entirely consistent with that predicted by a mathematical relationship between microsomal concentration, fumic, t1/2, CLint,app, and Km,app. These results demonstrate that when nonspecific binding is extensive, CLint,app is dependent on the arbitrary choice of microsomal concentration included in the incubation.
| |
Introduction |
|---|
|
|
|---|
In recent years, several methods have been
proposed to predict the human clearance of drug substances from data
obtained in liver microsomes (Lave et al., 1997
, 1999
; Obach, 1997
,
1999
; Obach et al., 1997
). Because of their predictive utility and ease of use, high-throughput liver microsomal lability assays are widely employed in drug discovery to prospectively identify compounds that
will have desirable pharmacokinetics in humans (Lave et al., 1999
;
Obach, 1999
; Kohl and Steinkellner, 2000
). The fact that nonspecific
microsomal binding has the potential to confound the accurate
prediction of clearance from these assays has been appreciated for
almost 40 years (Gillette, 1963
; Romer and Bickel, 1979
; Obach, 1996
;
McLure et al., 2000
). Consistent with established theory, correction
for free fraction differences between microsomes and plasma has
improved the predictive utility of microsomal data (Obach, 1996
, 1997
,
1999
; Obach et al., 1997
; Carlile et al., 1999
). In contrast, accurate
predictions of hepatic clearance have also been made without the need
for such a correction (Obach, 1999
). In an analysis of 29 clinical
compounds of known clearance by Obach et al., accounting for free
fraction differences had the largest impact on acidic drugs (Obach,
1999
). In contrast, the clearances of basic compounds were predicted
with equivalent or improved accuracy by disregarding all protein
binding data. In that data set, the free fraction differences between
microsomes and plasma were 3 ± 1.6-fold for bases and 101 ± 148-fold
for acids. When viewed in this manner, that data supports the general and intuitive concept that free fraction corrections are more likely to
be required when differences in binding between microsomes and plasma
are large. Since the extent of binding and the necessity of binding
corrections are difficult to predict a priori, trends have been
examined according to physiochemical properties (Obach, 1999
).
Regardless of these physiochemical properties, differences in the
concentrations of nonspecific binding components among these matrices
are expected to influence unbound fraction in a nonlinear manner (Romer
and Bickel, 1979
). When the overall extent of binding is low, less than
proportional changes in free fraction are expected as the concentration
of binding components are increased. As the average free fraction of
the basic compounds in the study by Obach et al. was 32 ± 20%,
the accuracy of predicted clearance in the absence of binding
considerations may reflect this nonlinear relationship (Obach, 1999
).
In contrast, when binding is extensive, increases in the concentrations
of nonspecific binding components within plasma alone may be expected
to decrease free fraction in a linear manner (Romer and Bickel, 1979
).
Since bases can have microsomal free fractions much less than 10%,
significant binding corrections may be required in these instances to
accurately predict intrinsic clearance (McLure et al., 2000
). When
protein binding considerations are disregarded under these
circumstances, even agreement of intrinsic clearance projections among
individual microsomal assays may depend upon the coincidental presence
of equivalent concentrations of nonspecific binding components. The potential impact of such a phenomenon is suggested by literature reports of microsomal protein concentrations varying as much as 200-fold among laboratories (Obach, 1999
; Venkatakrishnan et al., 2000
). As such, when nonspecific binding is extensive and binding considerations are disregarded, accurate predictions of in vivo clearance may be fortuitous. Therefore, the purpose of this work was to
theoretically and experimentally illustrate the expected influence of
microsomal concentration on estimates of
fumic,1
CLint,app, Km,app,
and t1/2. The term microsomal
concentration was used to represent the relative concentration
differences in all binding components and enzymes used throughout the
study. Concentration differences in both defined and undefined
microsomal components were achieved through 5-fold differences in the
total amount of microsomal protein added to the incubation mixture. Two
compounds were chosen to represent situations where differences in the
concentrations of nonspecific binding components are expected to have
maximal (high nonspecific binding) and minimal (low nonspecific binding) influence on free fraction (Romer and Bickel, 1979
).
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
Compounds A and B and all internal standards were obtained from
Pfizer's proprietary sample bank (Groton, CT). The physiochemical properties of these two compounds are reported in Table
1. All compounds were >99% pure, as
determined by high-pressure liquid chromatography. Pooled human
liver microsomes (n > 56) were obtained from an
in-house bank of liver microsomes maintained at Pfizer Global Research
and Development (Groton, CT). Microsomal CYP content, estimated as
described previously (Omura and Sato, 1964
), was 0.43 nmol/mg of
protein. Solvents and other reagents were obtained from common sources
and were of reagent grade or better. NADPH (97% purity) was obtained
from Sigma Chemical Co. (St. Louis, MO).
|
Theoretical Impact of Microsomal Concentration on Free Fraction.
Assuming equilibrium kinetics and nonsaturable binding, the
relationship between free fraction (fumic),
dissociation constant (Kd), and binding
component concentration (B) can be written in a manner
consistent with that previously described in the literature (Romer and
Bickel, 1979
).
|
(1) |
|
(2) |
Theoretical Impact of Microsomal Concentration on Half-Life.
Assuming that only free substrate fumic · [S] is able to be acted upon by enzyme [E],
and Vmax is expressed in terms of a catalysis rate constant (kcat) and the
total mass of enzyme (Etotal), the velocity
(v) is defined in eq. 3 by the Michaelis-Menten equation.
|
(3) |
fumic · [S]) and expressing velocity in terms of half-life
(t1/2) and total mass of substrate
(Stotal), one obtains eq. 4.
|
(4) |
|
(5) |
|
(6) |
|
(7) |
Theoretical Impact of Microsomal Concentration on
Km.
The definition of apparent Km is provided
in eq. 8.
|
(8) |
|
(9) |
Metabolic Incubations. The microsomal clearances of compounds A and B were examined in pooled human liver microsomes at total protein concentrations of 0.46 and 2.3 mg/ml, corresponding to total CYP concentrations of 0.20 and 1.0 µM, respectively. These concentrations were achieved through dilution of a stock suspension of microsomes with sodium phosphate buffer (pH 7.4, 100 mM) to assure a 5-fold difference in the concentration of all nonspecific binding components. Selected substrate concentrations (0.1-300 µM) were incubated with magnesium chloride (5 mM) and NADPH (2 mM) in 0.75 ml of sodium phosphate buffer (pH 7.4, 100 mM) at 37°C. Microsomes were preincubated for approximately 5 min before the reaction was initiated by the addition of NADPH. Aliquots of 100 µl were removed from the incubations at 0, 5, 10, 15, 30, and 45 min and added to 100 µl of acetonitrile to terminate further metabolism. All incubations were conducted in triplicate.
Equilibrium Dialysis.
Compounds A and B (3.0 µM) were mixed with the indicated pooled human
liver microsomes suspended in magnesium chloride (5 mM) and sodium
phosphate buffer (pH 7.4, 100 mM). The mixture (1.0 ml) was subject to
equilibrium dialysis versus 1.0 ml of sodium phosphate buffer (pH 7.4, 100 mM) at 37°C using a Spectrum semi-micro apparatus (Spectrum
Industries, Los Angeles, CA) and Spectra-Por no.2 membranes with
molecular weight cutoff of 12 to 14 kDa. Equilibrium was achieved by
rotating the cells at 25 rpm for 4.5 h (Obach, 1997
). All
experiments were performed in triplicate.
High-Pressure Liquid Chromatography Analysis. Quantitation of compound A was accomplished using an LC-MS assay. Samples were injected (1-5 µl; HTSPal Autosampler, CTC Analytics, Carrboro, NC) onto a Primesphere 2.0- × 30-mm 5-µm C18 column (Phenomenex, Torrance, CA) with a run time of 2.0 min. Analytes were eluted with acetonitrile/ammonium acetate (pH 6.8, 10 mM)/isopropanol (60:39:1, v/v/v) at a flow rate of 0.550 ml/min produced by a Shimadzu LC-10ADVP binary pump (Shimadzu, Kyoto, Japan). From 0.4 to 2.0 min the entire column effluent entered the Turbo Ionspray source (500°C, 7 liters/min nitrogen) of a PE-Sciex API-150 single quadrupole mass spectrometer (Concord, ON, Canada). Compound A and the internal standard were measured using single ion monitoring (m/z = 442.2 and 480.2, respectively) with positive ionization at a retention time of 0.7 min.
Quantitation of compound B was accomplished using an LC-MS/MS assay. Samples were injected (1-5 µl; HTSPal Autosampler) onto a monitor 3.0- × 30-mm 3-µM C18 column (Column Engineering, Ontario, Canada) maintained a 37°C with a run time of 4.5 min. Analytes were eluted with a high-pressure linear gradient program consisting of methanol ("A") and ammonium acetate (pH 6.8, 10 mM)/isopropanol (99:1, v/v) ("B") produced by two Shimadzu LC-10ADVP binary pumps and a 10-µl static mixer with a combined flow rate of 0.300 ml/min. An initial concentration of 20% A was immediately ramped to 100% A in 3 min and held for 0.5 min. The system was returned to the initial conditions in a single step and allowed to equilibrate for 1 min. From 1.5 to 4.0 min the entire column effluent entered the Turbo Ionspray source (500°C, 8 liters/min nitrogen) of a PE-Sciex API-3000 triple quadrupole mass spectrometer. Compound B and the internal standard were measured using multiple reaction monitoring (m/z = 411.2-339.2 and 466.1-380.1, respectively) with negative ionization at a retention time of 2.3 and 2.4 min, respectively. Standard curves were used for analysis of equilibrium dialysis, and microsomal incubation samples were used for enzyme kinetic calculations. Equilibrium dialysis samples were prepared by mixing microsome samples with control buffer or buffer samples with control microsomes to yield an identical matrix, which were combined with internal standard in acetonitrile to precipitate proteins prior to analysis of supernatant. Samples from microsomal incubations were vortexed and centrifuged, and an aliquot of supernatant was combined with internal standard for analysis.Calculations.
The initial reaction velocity (v0) was
calculated by multiplying the nominal substrate concentration at time 0 ([S]0) by the slope of the
log-linear regression from the concentration versus time relationship
(k) and dividing by the protein concentration of the
incubation, v0 =
k · [S]0/[P]. The velocity
data were plotted in double reciprocal and Eadie-Hofstee plots to
confirm enzyme kinetics consistent with a single metabolic site.
Apparent Km and
Vmax were estimated by modeling velocity
versus substrate concentration using the Michaelis-Menten equation and
WinNonlin 2.1 (Pharsight Inc., Palo Alto, CA). In contrast, microsomal
half-lives were calculated using the slope of the log-linear regression
from the concentration versus time relationship (k),
t 1/2 =
ln(2)/k. Consistent with the required assumptions outlined in the theoretical section, half-life was reported for the lowest concentration examined (such that S
Km). Intrinsic
clearance was calculated from half-life using the following formula
(Obach et al., 1997
).
|
| |
Results |
|---|
|
|
|---|
Effect of Microsomal Concentration on Free Fraction (Table 2). A 5-fold increase in microsomal concentration was associated with an equivalent 5-fold decrease in free fraction of compound A (high nonspecific binding) from 0.055 to 0.012 (Table 2). In contrast, the free fraction of compound B (low nonspecific binding) was not proportionally influenced by microsomal concentration (Table 2).
|
Effect of Microsomal Concentration on Half-Life and CLint,app (Table 2). The half-life of compound A was independent of microsomal concentration. In this case, the decrease in CLint,app from 80 to 17 ml/min/kg was proportional to the increase in microsomal concentration. For compound B, the 5-fold increase in microsomal concentration was associated with a decrease in half-life from 19 to 5.9 min. In this case, there was no proportional change in CLint,app. Correction of CLint,app for the free fraction yielded estimates that were independent of microsomal concentration for both compounds.
Effect of Microsomal Concentration on Km,app. The Km,app of compound A increased proportionally to the 5-fold increase in microsomal concentration. In this case, a 5-fold increase in microsomal concentration was associated with an equivalent increase in Km,app from 13 to 70 µM (Fig. 1, Table 2). In contrast, the Km,app of compound B was not proportionally influenced by changes in microsomal concentration (Fig. 2, Table 2). Since Vmax is normalized to total protein concentration it was unaffected for both compounds A and B (Fig. 2, Table 2). In addition, correction of Km,app for free fraction yielded estimates that appeared to be independent of microsomal concentration for both compounds.
|
|
| |
Discussion |
|---|
|
|
|---|
Hepatic microsomal lability represents one of the simplest and
most widely used tools to predict human clearance during the drug
discovery process (Iwatsubo et al., 1997
; Rodrigues, 1997
; Obach,
1999
). Two methods are commonly employed, including the t1/2 method, in which the first order rate
of metabolism is determined at low substrate concentrations, and the
enzyme kinetic method, in which Vmax and
Km are determined (Rane et al., 1977
; Obach et al., 1997
). Estimates of in vivo intrinsic clearance are typically made through the use of scaling factors applied to the observed in
vitro data on the basis of protein concentration (Houston, 1994
). As
previously reviewed, this use of microsomes requires many assumptions,
including one that the substrate is freely available for metabolism
(Houston and Carlile, 1997
). Many compounds can bind nonspecifically to
microsomes, thereby invalidating this assumption (Obach, 1996
, 1997
,
1999
; Obach et al., 1997
; Venkatakrishnan et al., 2000
). In these
cases, increasing concentrations of nonspecific binding components
within the incubation will decrease the apparent intrinsic clearance of
compounds that bind to liver microsomes (Gillette, 1963
; Obach, 1997
;
McLure et al., 2000
). Despite the clear implications of these findings
for scaling intrinsic clearance, methods disregarding all protein
binding considerations can yield clearance projections of the same
accuracy as those that account for the extent of plasma and microsomal
binding (Obach, 1999
). Discussion of this phenomenon in the literature
frequently follows a delineation of the impact of binding corrections
and experimental outcomes around physiochemical properties (Obach,
1999
; McLure et al., 2000
). Although the conclusions of these analyses
may have empiric value, they do not directly relate the underlying factors known to influence free fraction to the experimental outcomes in a quantitative manner. As such, relationships between the necessity of nonspecific binding considerations and physiochemical properties should be tenuously considered when conducting studies to characterize additional compounds. Herein, we have theoretically and experimentally illustrated the expected impact of microsomal concentration on several
parameters that are commonly reported as measures of microsomal lability. Projected and observed results were quantitatively compared in terms of -fold changes to fumic,
t1/2, CLint,app, and
Km,app. The theories were derived from very
simple rearrangements of the relationship between free fraction and
binding component concentration (Romer and Bickel, 1979
). Two
proprietary compounds were chosen to experimentally illustrate two
extremes depicted by the derived theories, viz.; high nonspecific
binding and low nonspecific binding. The highly bound representative
(compound A, fumic = 0.055) was a basic and
highly lipophilic compound, whereas the compound representative of low
binding (compound B, fumic = 0.86) was a slightly
less lipophilic acid (Table 1). Although the structures of these
compounds are not revealed, we submit that the conclusions have general applicability to other compounds regardless of specific chemical structures or physiochemical characteristics.
High Nonspecific Binding.
A 5-fold increase in microsomal concentration was associated with a
proportional decrease in the free fraction of compound A (Table 2). No
difference in metabolic half-life was observed; however, scaling of the
observed microsomal t1/2 to an estimate of
apparent intrinsic clearance resulted in a 5-fold lower value at the
higher microsomal concentration (Table 2). Consistent with this result,
the Km,app of compound A increased
proportionally to the increase in microsomal concentration (Table 2,
Fig. 1). Each of these observations is consistent with the expected
behavior for a highly bound compound predicted by eqs. 2, 7, and 9. We conclude that the 5-fold difference in CYP concentration is offset by
an inversely proportional change in free fraction. This conclusion was
supported when correction for the free fraction available for
metabolism resulted in virtually identical estimates of intrinsic clearance under both conditions (Table 2). Although these findings are
in general agreement with recent simulations published by McLure et al.
(2000)
, the lack of a direct quantitative relationship between these
variables in that study prevents a detailed comparison. We expect that
this class of compounds will frequently require the correction factor
previously proposed by Obach (1996)
for free fraction differences
between plasma and microsomes to accurately predict clearance in vivo.
In this circumstance, the quantitative differences in protein and lipid
content between microsomes and plasma alone could reasonably be
expected to result in significant differences in the free fraction
between these two matrices. Since the free fraction in microsomes is
determined, in part, by the choice of microsomal concentration in the
incubation, equivalent free fractions between plasma and microsomes
should be considered coincidental. It is therefore unlikely that the
clearance of these compounds will be accurately predicted by
disregarding all binding. These data also suggest that one could avoid
indiscriminate and labor intensive protein binding studies by
determining the metabolic half-life at two different microsomal
concentrations. If half-life is unchanged, then the compound may be
highly bound. If half-life is changed proportionally then the compound
is expected to have a low extent of nonspecific binding as described below.
Low Nonspecific Binding.
Less than proportional changes in the free fraction of compound B were
observed relative to microsomal concentration (Table 2). It is
important to note that a nonlinear decrease in free fraction was
observed at the higher microsomal concentration. This is consistent
with eq. 1, which predicts that compounds with high free fractions will
be influenced nonlinearly by changes in the concentrations of
nonspecific binding components. At 5-fold higher microsomal
concentration, the t1/2 of compound B was
decreased by greater than 3-fold (Table 2). The slight difference in
free fraction, observed in this case, contributes to the slightly less than proportional difference in t1/2 (Table
2). Scaling of the observed microsomal t1/2
to CLint,app, resulted in estimates that were
relatively independent of microsomal concentration (Table 2).
Consistent with this result, the Km,app of
compound B was also relatively independent of microsomal concentration
(Table 2, Fig. 2). Again, the slight difference in free fraction may account for the small differences in CLint,app
and Km,app. This is evidenced by the even
smaller differences in these parameters when corrected for free
fraction (Table 2). Each of these observations is consistent with the
expected behavior predicted by eqs. 2, 7, and 9 for a compound with low
nonspecific binding. In this case, we conclude that the increase in CYP
afforded by increasing the microsomal concentration within the
incubation is accomplished without a significant effect on the free
fraction of substrate available for metabolism. Because
t1/2 from the microsomes decreases proportionally, scaling of intrinsic clearance results in estimates that are independent of microsome concentration. We expect that this
class of compounds may not require the correction factor previously
proposed by Obach (1996)
for free fraction differences between plasma
and microsomes to accurately predict clearance in vivo. However, it is
important to note that highly free compounds in microsomes may still be
highly bound to plasma proteins. In such cases, it may be possible to
ignore in vitro microsomal protein binding but necessary to account for
plasma protein binding when predicting clearance.
| |
Footnotes |
|---|
Received April 4, 2001; accepted July 19, 2001.
Tristan S. Maurer, Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research, Inc., Eastern Point Road, Groton, CT 06340. E-mail: tristan_s_maurer{at}groton.pfizer.com
| |
Abbreviations |
|---|
Abbreviations used are: fumic, microsomal fraction unbound; CLint,app, apparent intrinsic clearance; CYP, cytochrome P450; Km,app, apparent Michaelis-Menten constant.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Gao, L. Yao, H. W. Mathieu, Y. Zhang, T. S. Maurer, M. D. Troutman, D. O. Scott, R. B. Ruggeri, and J. Lin In Silico Modeling of Nonspecific Binding to Human Liver Microsomes Drug Metab. Dispos., October 1, 2008; 36(10): 2130 - 2135. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Zaya, R. N. Hines, and J. C. Stevens Epirubicin Glucuronidation and UGT2B7 Developmental Expression Drug Metab. Dispos., December 1, 2006; 34(12): 2097 - 2101. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Raghavan, D. Zhang, M. Zhu, J. Zeng, and L. Christopher CYP2D6 CATALYZES 5-HYDROXYLATION OF 1-(2-PYRIMIDINYL)-PIPERAZINE, AN ACTIVE METABOLITE OF SEVERAL PSYCHOACTIVE DRUGS, IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., February 1, 2005; 33(2): 203 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Walsky and R. S. Obach VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Foti and M. B. Fisher IMPACT OF INCUBATION CONDITIONS ON BUFURALOL HUMAN CLEARANCE PREDICTIONS: ENZYME LABILITY AND NONSPECIFIC BINDING Drug Metab. Dispos., March 1, 2004; 32(3): 295 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Margolis and R. S. Obach Impact of Nonspecific Binding to Microsomes and Phospholipid on the Inhibition of Cytochrome P4502D6: Implications for Relating in Vitro Inhibition Data to in Vivo Drug Interactions Drug Metab. Dispos., May 1, 2003; 31(5): 606 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Tran, L. L. von Moltke, K. Venkatakrishnan, B. W. Granda, M. A. Gibbs, R. S. Obach, J. S. Harmatz, and D. J. Greenblatt Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors Drug Metab. Dispos., December 1, 2002; 30(12): 1441 - 1445. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Austin, P. Barton, S. L. Cockroft, M. C. Wenlock, and R. J. Riley The Influence of Nonspecific Microsomal Binding on Apparent Intrinsic Clearance, and Its Prediction from Physicochemical Properties Drug Metab. Dispos., December 1, 2002; 30(12): 1497 - 1503. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Fisher, K. Yoon, M. L. Vaughn, T. J. Strelevitz, and R. S. Foti Flavin-Containing Monooxygenase Activity in Hepatocytes and Microsomes: In Vitro Characterization and In Vivo Scaling of Benzydamine Clearance Drug Metab. Dispos., October 1, 2002; 30(10): 1087 - 1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Obach and A. E. Reed-Hagen Measurement of Michaelis Constants for Cytochrome P450-Mediated Biotransformation Reactions Using a Substrate Depletion Approach Drug Metab. Dispos., July 1, 2002; 30(7): 831 - 837. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||